Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,160,208
  • Shares Outstanding, K 1,293,620
  • Annual Sales, $ 26,107 M
  • Annual Income, $ 4,628 M
  • 36-Month Beta 1.01
  • Price/Sales 3.48
  • Price/Cash Flow 7.23
  • Price/Book 3.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.63
  • Number of Estimates 8
  • High Estimate 2.04
  • Low Estimate 1.34
  • Prior Year 1.60
  • Growth Rate Est. (year over year) +1.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.81 +3.56%
on 11/27/18
72.90 -6.52%
on 12/03/18
-4.33 (-5.97%)
since 11/07/18
3-Month
65.81 +3.56%
on 11/27/18
79.61 -14.40%
on 10/03/18
-4.07 (-5.64%)
since 09/07/18
52-Week
64.27 +6.04%
on 05/03/18
89.54 -23.89%
on 01/29/18
-4.57 (-6.28%)
since 12/07/17

Most Recent Stories

More News
Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis

Biogen (BIIB) obtains a license to develop and commercialize BIIB067 from Ionis Pharmaceuticals. The candidate is being developed for treatment of ALS with SOD1 mutations.

IONS : 53.12 (-5.23%)
GILD : 68.15 (-2.91%)
BIIB : 316.73 (-3.05%)
ALXN : 115.60 (-4.49%)
Gilead's (GILD) Harvoni and Descovy Get Approval in China

Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.

SGMO : 11.31 (-5.20%)
ABBV : 86.96 (-3.73%)
GILD : 68.15 (-2.91%)
GSK : 37.30 (-0.32%)
Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China

This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector....

CELG : 70.08 (-3.74%)
BLUE : 102.23 (-6.08%)
VRTX : 172.21 (-4.12%)
GILD : 68.15 (-2.91%)
AMGN : 191.44 (-3.80%)
Today's Research Reports on Trending Tickers: Gilead Sciences and Celgene

NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China's ability to close a trade agreement weighed on the markets. The Dow Jones Industrial...

GILD : 68.15 (-2.91%)
Amgen's BiTE Immunotherapies Show Promise in Early Studies

Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA

GILD : 68.15 (-2.91%)
AMGN : 191.44 (-3.80%)
VNDA : 27.60 (-6.19%)
ALXN : 115.60 (-4.49%)
Gilead (GILD) Announces Data on CAR T Therapy Candidate

Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.

SGMO : 11.31 (-5.20%)
NVS : 87.08 (-2.21%)
GILD : 68.15 (-2.91%)
GSK : 37.30 (-0.32%)
China's National Medical Products Administration Approves Harvoni(R) (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6

--Harvoni Achieved Cure Rate (SVR12) of 100 Percent in Clinical Trial of Chinese Patients with Genotype 1--

GILD : 68.15 (-2.91%)
China National Medical Products Administration Approves Descovy(R) (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the China National Medical Products Administration (NMPA) has approved Descovy(R) (emtricitabine 200 mg/tenofovir alafenamide 10...

GILD : 68.15 (-2.91%)
Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

-- Based on these Data, the Phase 2 Portion of ZUMA-3 is Now Enrolling --

GILD : 68.15 (-2.91%)
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $70.86, marking a -1.5% move from the previous day.

GILD : 68.15 (-2.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 70.79
1st Resistance Point 69.47
Last Price 68.15
1st Support Level 67.36
2nd Support Level 66.57

See More

52-Week High 89.54
Fibonacci 61.8% 79.89
Fibonacci 50% 76.90
Fibonacci 38.2% 73.92
Last Price 68.15
52-Week Low 64.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar